Do analysts recommend PRPO or BNGO?

Bionano Genomics has a consensus target price of $6.00, suggesting a potential upside of 440.54%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PRPO or BNGO more profitable?

Precipio has a net margin of -3.57% compared to Bionano Genomics' net margin of -109.94%. Precipio's return on equity of -6.73% beat Bionano Genomics' return on equity. Company Net Margins Return on Equity Return on Assets Precipio -3.57% -6.73% -4.49% Bionano Genomics -109.94% -71.38% -43.07%

Is BNGO or DAIO more profitable?

Data I/O has a net margin of -41.85% compared to Bionano Genomics' net margin of -109.94%. Data I/O's return on equity of -54.33% beat Bionano Genomics' return on equity. Company Net Margins Return on Equity Return on Assets Bionano Genomics -109.94% -71.38% -43.07% Data I/O -41.85% -54.33% -36.75%

Do analysts recommend BNGO or AATC?

Bionano Genomics currently has a consensus target price of $6.00, indicating a potential upside of 440.54%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts clearly believe Bionano Genomics is more favorable than Autoscope Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Autoscope Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate ASTC or BNGO?

Bionano Genomics has a consensus price target of $6.00, suggesting a potential upside of 440.54%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Astrotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astrotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Bionano Genomics (BNGO) Competitors

$1.11 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+0.90%)

As of 07/24/2026 07:34 PM Eastern

Compare

BNGO vs. PRPO, DAIO, AATC, CLIR, and ASTC

Should you buy Bionano Genomics stock or one of its competitors? MarketBeat compares Bionano Genomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bionano Genomics include Precipio (PRPO), Data I/O (DAIO), Autoscope Technologies (AATC), ClearSign Technologies (CLIR), and Astrotech (ASTC). These companies are all part of the "measuring and control equipment" industry.

How does Bionano Genomics compare to Precipio?

Precipio (NASDAQ:PRPO) and Bionano Genomics (NASDAQ:BNGO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Precipio has higher earnings, but lower revenue than Bionano Genomics. Precipio is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	1.76	-$360K	-$0.47	N/A
Bionano Genomics	$28.51M	0.45	-$26.40M	-$4.37	N/A

Bionano Genomics has a consensus target price of $6.00, suggesting a potential upside of 440.54%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.5% of Precipio shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 16.6% of Precipio shares are owned by company insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Precipio has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

In the previous week, Precipio had 1 more articles in the media than Bionano Genomics. MarketBeat recorded 2 mentions for Precipio and 1 mentions for Bionano Genomics. Bionano Genomics' average media sentiment score of 1.87 beat Precipio's score of 0.94 indicating that Bionano Genomics is being referred to more favorably in the news media.

Company	Overall Sentiment
Precipio	Positive
Bionano Genomics	Very Positive

Precipio has a net margin of -3.57% compared to Bionano Genomics' net margin of -109.94%. Precipio's return on equity of -6.73% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-3.57%	-6.73%	-4.49%
Bionano Genomics	-109.94%	-71.38%	-43.07%

Summary

Precipio and Bionano Genomics tied by winning 8 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to Data I/O?

Bionano Genomics (NASDAQ:BNGO) and Data I/O (NASDAQ:DAIO) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Data I/O had 3 more articles in the media than Bionano Genomics. MarketBeat recorded 4 mentions for Data I/O and 1 mentions for Bionano Genomics. Bionano Genomics' average media sentiment score of 1.87 beat Data I/O's score of 0.72 indicating that Bionano Genomics is being referred to more favorably in the media.

Company	Overall Sentiment
Bionano Genomics	Very Positive
Data I/O	Positive

Data I/O has a net margin of -41.85% compared to Bionano Genomics' net margin of -109.94%. Data I/O's return on equity of -54.33% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-109.94%	-71.38%	-43.07%
Data I/O	-41.85%	-54.33%	-36.75%

Data I/O has lower revenue, but higher earnings than Bionano Genomics. Data I/O is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.45	-$26.40M	-$4.37	N/A
Data I/O	$21.50M	1.36	-$5.24M	-$0.84	N/A

11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 37.0% of Data I/O shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Comparatively, 4.1% of Data I/O shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bionano Genomics presently has a consensus price target of $6.00, suggesting a potential upside of 440.54%. Data I/O has a consensus price target of $5.11, suggesting a potential upside of 63.78%. Given Bionano Genomics' higher probable upside, equities research analysts clearly believe Bionano Genomics is more favorable than Data I/O.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Data I/O	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80

Bionano Genomics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Data I/O has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Summary

Data I/O beats Bionano Genomics on 11 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to Autoscope Technologies?

Bionano Genomics (NASDAQ:BNGO) and Autoscope Technologies (NASDAQ:AATC) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

11.4% of Bionano Genomics shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by company insiders. Comparatively, 21.6% of Autoscope Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bionano Genomics currently has a consensus target price of $6.00, indicating a potential upside of 440.54%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts clearly believe Bionano Genomics is more favorable than Autoscope Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Autoscope Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Bionano Genomics and Bionano Genomics both had 1 articles in the media. Bionano Genomics' average media sentiment score of 1.87 beat Autoscope Technologies' score of 0.00 indicating that Bionano Genomics is being referred to more favorably in the media.

Company	Overall Sentiment
Bionano Genomics	Very Positive
Autoscope Technologies	Neutral

Autoscope Technologies has a net margin of 37.59% compared to Bionano Genomics' net margin of -109.94%. Autoscope Technologies' return on equity of 27.06% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-109.94%	-71.38%	-43.07%
Autoscope Technologies	37.59%	27.06%	23.97%

Autoscope Technologies has lower revenue, but higher earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Autoscope Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.45	-$26.40M	-$4.37	N/A
Autoscope Technologies	$8.93M	3.40	$6.62M	$0.25	22.04

Bionano Genomics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Autoscope Technologies has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

Summary

Autoscope Technologies beats Bionano Genomics on 8 of the 15 factors compared between the two stocks.

How does Bionano Genomics compare to ClearSign Technologies?

ClearSign Technologies (NASDAQ:CLIR) and Bionano Genomics (NASDAQ:BNGO) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

ClearSign Technologies has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

ClearSign Technologies has higher earnings, but lower revenue than Bionano Genomics. ClearSign Technologies is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearSign Technologies	$5.23M	4.21	-$5.50M	-$0.99	N/A
Bionano Genomics	$28.51M	0.45	-$26.40M	-$4.37	N/A

In the previous week, ClearSign Technologies had 1 more articles in the media than Bionano Genomics. MarketBeat recorded 2 mentions for ClearSign Technologies and 1 mentions for Bionano Genomics. Bionano Genomics' average media sentiment score of 1.87 beat ClearSign Technologies' score of 0.65 indicating that Bionano Genomics is being referred to more favorably in the news media.

Company	Overall Sentiment
ClearSign Technologies	Positive
Bionano Genomics	Very Positive

Bionano Genomics has a net margin of -109.94% compared to ClearSign Technologies' net margin of -111.66%. ClearSign Technologies' return on equity of -61.24% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearSign Technologies	-111.66%	-61.24%	-45.80%
Bionano Genomics	-109.94%	-71.38%	-43.07%

24.0% of ClearSign Technologies shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 5.2% of ClearSign Technologies shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ClearSign Technologies presently has a consensus target price of $20.00, suggesting a potential upside of 473.07%. Bionano Genomics has a consensus target price of $6.00, suggesting a potential upside of 440.54%. Given ClearSign Technologies' higher probable upside, analysts clearly believe ClearSign Technologies is more favorable than Bionano Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearSign Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ClearSign Technologies beats Bionano Genomics on 8 of the 14 factors compared between the two stocks.

How does Bionano Genomics compare to Astrotech?

Astrotech (NASDAQ:ASTC) and Bionano Genomics (NASDAQ:BNGO) are both small-cap measuring and control equipment companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Astrotech has a beta of 4.77, suggesting that its stock price is 377% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

Bionano Genomics has a net margin of -109.94% compared to Astrotech's net margin of -1,397.82%. Bionano Genomics' return on equity of -71.38% beat Astrotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrotech	-1,397.82%	-81.85%	-65.46%
Bionano Genomics	-109.94%	-71.38%	-43.07%

24.4% of Astrotech shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 16.8% of Astrotech shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Astrotech has higher earnings, but lower revenue than Bionano Genomics. Astrotech is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrotech	$1.05M	12.34	-$13.85M	-$8.41	N/A
Bionano Genomics	$28.51M	0.45	-$26.40M	-$4.37	N/A

In the previous week, Astrotech had 4 more articles in the media than Bionano Genomics. MarketBeat recorded 5 mentions for Astrotech and 1 mentions for Bionano Genomics. Bionano Genomics' average media sentiment score of 1.87 beat Astrotech's score of 0.63 indicating that Bionano Genomics is being referred to more favorably in the news media.

Company	Overall Sentiment
Astrotech	Positive
Bionano Genomics	Very Positive

Bionano Genomics has a consensus price target of $6.00, suggesting a potential upside of 440.54%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Astrotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Bionano Genomics beats Astrotech on 10 of the 16 factors compared between the two stocks.

Get Bionano Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNGO vs. The Competition

Export

Metric	Bionano Genomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.74M	$3.67B	$7.06B	$12.20B
Dividend Yield	N/A	2.19%	2.67%	9.41%
P/E Ratio	-0.25	21.29	27.14	23.63
Price / Sales	0.45	297.82	582.30	111.98
Price / Cash	N/A	153.89	49.81	58.78
Price / Book	0.25	7.88	10.28	6.01
Net Income	-$26.40M	$23.86M	$3.60B	$331.99M
7 Day Performance	-3.48%	-3.82%	-1.27%	-0.63%
1 Month Performance	-2.63%	-4.45%	-1.67%	-3.04%
1 Year Performance	-67.16%	33.01%	18.25%	13.30%

Bionano Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNGO Bionano Genomics	2.6279 of 5 stars	$1.11 flat	$6.00 +440.5%	-67.2%	$12.74M	$28.51M	N/A	300	Positive News
PRPO Precipio	0.5537 of 5 stars	$23.48 +0.4%	N/A	+63.2%	$42.28M	$24.05M	N/A	60	Upcoming Earnings
DAIO Data I/O	2.5043 of 5 stars	$3.37 +4.2%	$5.11 +51.9%	-6.3%	$31.46M	$21.50M	N/A	100	Upcoming Earnings Analyst Upgrade Short Interest Increase
AATC Autoscope Technologies	N/A	$5.60 flat	N/A	-28.4%	$30.88M	$8.93M	6.36	40	News Coverage
CLIR ClearSign Technologies	2.7234 of 5 stars	$3.37 -0.1%	$20.00 +494.2%	-41.4%	$21.45M	$5.23M	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNGO) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Competitors

BNGO vs. PRPO, DAIO, AATC, CLIR, and ASTC

How does Bionano Genomics compare to Precipio?

Summary

How does Bionano Genomics compare to Data I/O?

Summary

How does Bionano Genomics compare to Autoscope Technologies?

Summary

How does Bionano Genomics compare to ClearSign Technologies?

Summary

How does Bionano Genomics compare to Astrotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Competitors

BNGO vs. PRPO, DAIO, AATC, CLIR, and ASTC

How does Bionano Genomics compare to Precipio?

Which has stronger earnings & valuation, PRPO or BNGO?

Do analysts recommend PRPO or BNGO?

Do insiders & institutionals hold more shares of PRPO or BNGO?

Which has more risk & volatility, PRPO or BNGO?

Does the media prefer PRPO or BNGO?

Is PRPO or BNGO more profitable?

Summary

How does Bionano Genomics compare to Data I/O?

Does the media refer more to BNGO or DAIO?

Is BNGO or DAIO more profitable?

Which has stronger earnings and valuation, BNGO or DAIO?

Do insiders & institutionals have more ownership in BNGO or DAIO?

Do analysts recommend BNGO or DAIO?

Which has more volatility and risk, BNGO or DAIO?

Summary

How does Bionano Genomics compare to Autoscope Technologies?

Do insiders and institutionals believe in BNGO or AATC?

Do analysts recommend BNGO or AATC?

Does the media refer more to BNGO or AATC?

Is BNGO or AATC more profitable?

Which has higher earnings and valuation, BNGO or AATC?

Which has more volatility & risk, BNGO or AATC?

Summary

How does Bionano Genomics compare to ClearSign Technologies?

Which has more volatility and risk, CLIR or BNGO?

Which has preferable valuation & earnings, CLIR or BNGO?

Does the media prefer CLIR or BNGO?

Is CLIR or BNGO more profitable?

Do insiders & institutionals have more ownership in CLIR or BNGO?

Do analysts prefer CLIR or BNGO?

Summary

How does Bionano Genomics compare to Astrotech?

Which has more risk and volatility, ASTC or BNGO?

Is ASTC or BNGO more profitable?

Do insiders and institutionals hold more shares of ASTC or BNGO?

Which has better valuation & earnings, ASTC or BNGO?

Does the media favor ASTC or BNGO?

Do analysts rate ASTC or BNGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools